Premium
The relation between hypoxia‐inducible factor (HIF)‐1alpha expression with p53 expression and outcome in surgically treated supraglottic laryngeal cancer
Author(s) -
Cabanillas R.,
Rodrigo J.P.,
Secades P.,
Astudillo A.,
Nieto C.S.,
Chiara M.D.
Publication year - 2009
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21243
Subject(s) - medicine , immunohistochemistry , larynx , immunostaining , lymph node , neck dissection , pathology , cancer , laryngeal neoplasm , population , oncology , surgery , environmental health
Objective The purpose of this study was to examine whether a relationship exists between HIF‐1α expression and the pro‐apoptotic protein p53 in supraglottic laryngeal squamous cell carcinomas (SCCs), which could provide information concerning patient prognosis. Methods The study population was composed of 106 previously untreated men with SCC of the supraglottic larynx. All the patients underwent surgical resection of the tumor and bilateral neck dissection. Immunohistochemical analysis of HIF‐1α and p53 protein expression was performed in relation with clinicopathological parameters and prognosis. Results HIF‐1α nuclear expression was detected in 71% of primary carcinomas and 55% of the paired lymph node metastases. There was a significant positive correlation between HIF‐1α and T‐classification but no associations were observed with other clinicopathological variables and with prognosis. There was no correlation between the expression of HIF‐1α and p53. HIF‐1α overexpression in combination with p53 immunostaining was not associated with disease recurrence or survival. Conclusion The data suggest that HIF‐1α expression does not have a prognostic value in surgically treated supraglottic laryngeal SCC, and that immunohistochemical determination of p53 does not allow improving the clinical significance of HIF‐1α. J. Surg. Oncol. 2009;99:373–378. © 2009 Wiley‐Liss, Inc.